JNJ Jan 2024 240.000 put
| Previous Close | 63.30 |
| Open | 63.45 |
| Bid | 65.60 |
| Ask | 66.85 |
| Strike | 240.00 |
| Expire Date | 2024-01-19 |
| Day's Range | 63.30 - 63.45 |
| Contract Range | N/A |
| Volume | |
| Open Interest | 7 |
- Motley Fool
Johnson & Johnson's Latest Talcum Powder Development Could Be Costly
Healthcare conglomerate Johnson & Johnson's (NYSE: JNJ) ongoing litigation over the alleged health effects of its talc-based baby powder continues to hang over the company's head. Recently, an appeals court ruled against Johnson & Johnson's attempt at using bankruptcy protection to shield itself from claims. An analyst from JPMorgan estimated that Johnson & Johnson's potential talc liabilities could approach $8 billion to $10 billion, which is no small pill to swallow.
- Motley Fool
2 Reasons to Buy Johnson & Johnson, and 2 Reasons to Sell
There are plenty of reasons why many investors enjoy holding shares in Johnson & Johnson (NYSE: JNJ), one of the world's largest healthcare businesses. With the company's impressive track record of dividend payments and its pipeline's massive throughput of new medicines, it's clear that this stock will be around for the foreseeable future. Johnson & Johnson's product mix makes it worth buying in times like now when inflation is higher than average.
- Motley Fool
1 Resilient Blue Chip Stock to Buy on the Dip
Johnson & Johnson is facing issues that are causing investors to look elsewhere (more on those below). Let's look into why opportunistic investors should seriously consider buying shares of Johnson & Johnson as they sink. On Jan. 24, Johnson & Johnson released its fourth-quarter and full-year 2022 financial results.
